Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Clynes

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs)C P Duffy, C J Elliott, R A O'Connor, et al.
Cancer Chemotherapy and Pharmacology|April 28, 2006
A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancerR O'Connor, M O'Leary, J Ballot, et al.
Anticancer Research|May 22, 2004
Expression and prognostic relevance of Mcl-1 in breast cancerL O'Driscoll, D Cronin, S M Kennedy, et al.
BMC Cancer|March 3, 2017
The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validationD J Lundon, A Boland, M Prencipe, et al.
British Journal of Cancer|March 18, 2010
Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasisN Walsh, S Kennedy, A M Larkin, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs)C P Duffy, C J Elliott, R A O'Connor, et al.
Cancer Chemotherapy and Pharmacology|April 28, 2006
A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancerR O'Connor, M O'Leary, J Ballot, et al.
Anticancer Research|May 22, 2004
Expression and prognostic relevance of Mcl-1 in breast cancerL O'Driscoll, D Cronin, S M Kennedy, et al.
BMC Cancer|March 3, 2017
The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validationD J Lundon, A Boland, M Prencipe, et al.
British Journal of Cancer|March 18, 2010
Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasisN Walsh, S Kennedy, A M Larkin, et al.
Pageof 10